Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States
Authors:
Open Access
- 1 January 2018
- journal article
- research article
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 24 (1) , 29-38
Abstract
BACKGROUND: New 3-drug regimens have been developed and approved to treat multiple myeloma (MM). The absence of direct comparative data and the high cost of treatment support the need to assess the relative clinical and economic outcomes across all approved regimens. OBJECTIVE: To evaluate the cost-effectiveness of treatments for relapsed and/or refractory MM from a U.S. health system perspective. METHODS: We developed a partition survival model with 3 health states (progression-free, progression, and death) to evaluate the following regimens: carfilzomib (CFZ), elotuzumab (ELO), ixazomib (IX), daratumumab (DAR), and panobinostat (PAN) in combination with lenalidomide (LEN) or bortezomib (BOR) plus dexamethasone (DEX) in the second and/or third line of therapy. To estimate relative treatment effects, we developed a network meta-analysis and applied progression-free survival hazard ratios to baseline parametric progression-free survival functions derived from pooled data on LEN+DEX. We estimated overall su...Keywords
This publication has 20 references indexed in Scilit:
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY ThresholdNew England Journal of Medicine, 2014
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Time-dependent endpoints as predictors of overall survival in multiple myelomaBMC Cancer, 2013
- Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional surveySupportive Care in Cancer, 2012
- Improved curve fits to summary survival data: application to economic evaluation of health technologiesBMC Medical Research Methodology, 2011
- Network meta‐analysis of parametric survival curvesResearch Synthesis Methods, 2010
- Use of Indirect and Mixed Treatment Comparisons for Technology AssessmentPharmacoEconomics, 2008
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaNew England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaNew England Journal of Medicine, 2007
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005